Top Tweets for #OSIMERTINIB

And what will 2026 bring? Trials Likely to Shape Lung Cancer Care in 2026 EGFR-Mutant NSCLC: Beyond MARIPOSA and FLAURA2 1.TROPION-Lung14 / TROPION-Lung15 Datopotamab deruxtecan–based strategies in EGFR-mutant NSCLC, including combinations with EGFR TKIs. These trials test whether ADC-based intensification can outperform established TKI-centric first-line approaches. 2.FURVENT (ex20) Furmonertinib versus platinum-pemetrexed chemotherapy. A positive result would further validate next-generation EGFR TKIs as chemotherapy-replacing options in earlier lines. 3.Post-osimertinib combination studies (various sponsors) Several phase III programs are evaluating rational combinations aimed at delaying or overcoming resistance, with PFS and OS readouts expected to mature in 2026. ⸻ ADC Expansion Across Molecular Subsets 4.DESTINY-Lung04 Trastuzumab deruxtecan in earlier-line HER2-mutant NSCLC. A key test of whether HER2-targeted ADCs move from salvage to frontline-adjacent settings. 5.TROPION-Lung01 / Lung05 (mature OS analyses) Datopotamab deruxtecan across biomarker-unselected and selected NSCLC populations. These readouts will determine how broadly TROP2 ADCs can be deployed. 6.MET-directed ADC and combination programs Follow-on trials building on telisotuzumab vedotin, including combinations and earlier-line use, with efficacy and tolerability data expected to mature. ⸻ Immunotherapy: Refinement 7.Ivonescimab + chemotherapy phase III programs Bispecific PD-1/PD-L1 targeting strategies aimed at improving outcomes in PD-L1–low disease. Results will test whether bispecific checkpoint modulation adds meaningful benefit. 8.Novel checkpoint combinations (post-PD-1 era) Multiple large trials combining PD-1/PD-L1 blockade with new immune targets are expected to read out. These will clarify whether immunotherapy still has headroom in unselected NSCLC. ⸻ Early-Stage and Curative-Intent Disease 9.Perioperative targeted therapy trials (EGFR, ALK) Neoadjuvant and adjuvant studies incorporating TKIs or targeted combinations, with disease-free and overall survival endpoints maturing. These have the potential to reshape curative-intent care. 10.Perioperative immunotherapy intensification studies Trials evaluating extended or intensified neoadjuvant/adjuvant immunotherapy beyond current chemo-IO standards, testing whether deeper pathologic responses translate into cure. ⸻ Small-Cell Lung Cancer: Incremental but Real Movement 11.Post-platinum maintenance and consolidation strategies Trials building on atezolizumab maintenance and DLL3-targeted approaches, including combinations and sequencing studies, with interim or final results expected. 12.Next-generation T-cell engager programs in SCLC Follow-up phase II/III studies evaluating durability, safety, and survival beyond early DLL3 successes. ⸻ Detection, Stratification, and Minimal Residual Disease 13.Prospective AI-assisted lung cancer screening studies Trials validating AI-enhanced low-dose CT interpretation and risk stratification, with implications for screening scale-up rather than treatment per se. 14.ctDNA-guided intervention trials Minimal residual disease–directed escalation or de-escalation strategies in early-stage NSCLC, potentially redefining adjuvant therapy decision-making. ⸻ What to watch most closely •Whether ADC-based intensification improves survival without unacceptable pulmonary toxicity •Whether combination EGFR strategies prove deliverable outside ideal trial populations •Whether perioperative systemic therapy meaningfully increases cure, not just DFS •Whether SCLC gains durability, not just response •Whether AI and MRD quietly change who gets treated, and when